Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis
This study suggests that NIVO + IPI is cost-effective in both the United States and China at current price levels.
Authors
- Q. Li
- Ying Qin (ORCID: https://orcid.org/0000-0002-2956-8367)
- Qiuji Wu
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fpubh.2025.1726477
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00